NeuroSense previews Phase IIb trial plans for oral ALS drug
NeuroSense CEO Alon Ben-Noon reveals the target patient population and outcome measures of a planned Phase IIb ALS trial to…
By
NeuroSense CEO Alon Ben-Noon reveals the target patient population and outcome measures of a planned Phase IIb ALS trial to…
ByThe company anticipates reporting topline data from the trial in the second half of this year.
There is an emerging trend of specific sponsor types running MDD trials, as well as such studies embracing decentralisation.
ByTwo clinical trials will be conducted in the US and South Africa to assess intranasal doses of IGM-6268.
The trial will recruit 140 patients with biopsy-confirmed NASH.
Over the last five years, the conduct of clinical research in Africa has shown a steady increase, but the level…
ByThe trial will assess the tolerability, safety, efficacy and PK of two varying doses of suramin in adult LCS patients.
We've analysed 10 years' worth of clinical trials data from GlobalData to pick out key geographic trends.
ByThank you for subscribing to Clinical Trials Arena